Evidence map›Paper›PMID 34772647›Full record

Trial reportArchives of cardiovascular diseases2021

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial.

João Pedro Ferreira, Nicolas Girerd, Hans-Peter Brunner-La Rocca, Pierpaolo Pellicori, John G Cleland, Patrick Rossignol, Faiez Zannad

Abstract readLetterRandomized Controlled Trial
In one paragraph

Trial report in Archives of cardiovascular diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

João Pedro FerreiraInserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), centre d'investigations cliniques-plurithématique 1433, Nancy, France; Unidade de Investigaçao Cardiovascular-UnIC, Faculdade de Medicina Universidade do Porto, Porto, Portugal. Electronic address: j.ferreira@chru-nancy.fr.
Nicolas GirerdInserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), centre d'investigations cliniques-plurithématique 1433, Nancy, France.
Hans-Peter Brunner-La RoccaDepartment of Cardiology, Maastricht University, Maastricht, Netherlands.
Pierpaolo PellicoriClinical Trials Unit, Robertson Institute of Biostatistics, University of Glasgow, University Avenue, Glasgow, UK.
John G ClelandClinical Trials Unit, Robertson Institute of Biostatistics, University of Glasgow, University Avenue, Glasgow, UK.
Patrick RossignolInserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), centre d'investigations cliniques-plurithématique 1433, Nancy, France.
Faiez ZannadInserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), centre d'investigations cliniques-plurithématique 1433, Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin-Converting Enzyme 2SpironolactoneAngiotensin-Converting Enzyme InhibitorsHumansPeptidyl-Dipeptidase ARenin-Angiotensin SystemAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsPeptidyl-Dipeptidase ASpironolactoneCOVID-19SARS-CoV-2Spironolactone

Identifiers

PMID34772647
PMCPMC8576594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.